Arbutus Biopharma (ABUS) Goodwill & Intangibles (2015 - 2019)

Arbutus Biopharma (ABUS) has reported Goodwill & Intangibles for 5 consecutive years, with $66.3 million the latest figure, recorded in Q2 2019.

• Quarterly Goodwill & Intangibles fell 18.26% year-over-year to $66.3 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $66.3 million (down 18.26% YoY) and the FY2018 annual result came in at $66.3 million, down 20.12% from the prior year.
• Goodwill & Intangibles steadied at $66.3 million in Q2 2019 per ABUS's latest filing, from $66.3 million in the prior quarter.
• Over the last five years, Goodwill & Intangibles for ABUS reached as high as $546.1 million in Q2 2015 and fell as low as $66.3 million in Q3 2018.
• A 5-year average of $242.1 million and a median of $123.8 million in 2016 frame the typical range for Goodwill & Intangibles.
• The largest YoY upside for Goodwill & Intangibles was 5.57% in 2016 against a maximum downside of 75.97% in 2016.
• Year by year, Goodwill & Intangibles stood at $515.2 million in 2015, then tumbled by 75.97% to $123.8 million in 2016, then slumped by 32.95% to $83.0 million in 2017, then retreated by 20.12% to $66.3 million in 2018, then changed by 0.0% to $66.3 million in 2019.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $66.3 million, $66.3 million, and $66.3 million for Q2 2019, Q1 2019, and Q4 2018 respectively.